Recursion Pharmaceuticals
clinical target data from cohort analysis of phase prima trial for platinum sensitive ovarian cancer patients clinical benefit inhibitors is limited in negative proficient | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
68 of 143
Related slides by other companies
Ocuphire Pharma
Investor Presentation
November 2023
pipeline partnered with indication clinical phase phase phase product eyedrops night vision approved sept | Ocuphire Pharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights